Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4833649 | 0.88 | ALDH1A1 (0.47) | ALDH1A1MEN1KMT2AMAPTL3MBTL1 | |
| SCHEMBL4828811 | 0.85 | LMNA (0.50) | ALDH1A1MEN1KMT2AMAPTL3MBTL1 | |
| SCHEMBL4833687 | 0.84 | ALDH1A1 (0.43) | ALDH1A1MEN1KMT2AMAPTL3MBTL1 | |
| SCHEMBL4833683 | 0.84 | ALDH1A1 (0.43) | ALDH1A1MEN1KMT2AMAPTL3MBTL1 | |
| SCHEMBL4826489 | 0.83 | ALDH1A1 (0.49) | ALDH1A1KMT2ALMNARECQLSPHK2 | |
| SCHEMBL4826482 | 0.83 | ALDH1A1 (0.49) | ALDH1A1KMT2ALMNARECQLSPHK2 | |
| SCHEMBL4833682 | 0.82 | LMNA (0.50) | ALDH1A1L3MBTL1LMNARECQLSMN1; SMN2 | |
| SCHEMBL4828774 | 0.82 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2AMAPTL3MBTL1 | |
| SCHEMBL4828776 | 0.82 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2AMAPTL3MBTL1 | |
| SCHEMBL4833673 | 0.82 | LMNA (0.50) | ALDH1A1L3MBTL1LMNARECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293790-A1 | SUBSTITUTED ARYL OXIMES | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| US-7420083-B2 | Substituted aryloximes | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| EP-1663189-A1 | 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY)-PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIREMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBISIS | Wyeth (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005030193-A1 | 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY) -PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIRMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBOSIS | WYETH (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070584-A1 | Substituted aryloximes | WYETH (US) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070584-A1 | Substituted aryloximes | AHR, NQO1, AOX1 | ALDH1A1 269/4885MEN1 4290/4885KMT2A 416/4885 |
| US-20080293790-A1 | SUBSTITUTED ARYL OXIMES | HCCS, AOX1, TET2 | ALDH1A1 211/4885MEN1 4006/4885KMT2A 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.